Lipid-conjugated telomerase template antagonists sensitize resistant HER2-positive breast cancer cells to trastuzumab

Breast Cancer Research and Treatment

Volumn 118, Issue 1, 2009, Pages 21-32

  Goldblatt, Erin M ^a   Erickson, Priscilla A ^b   Gentry, Erin R ^a,b   Gryaznov, Sergei M ^c   Herbert, Brittney Shea ^a  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GERON CORPORATION   (United States)

Author keywords

Breast cancer; Combination therapy; GRN163L; HER2; Telomerase; Thio phosphoramidates

Indexed keywords

5 (2 BENZOTHIAZOLYL)THIOMETHYL 4 HYDROXY 3 METHOXYBENZYLIDENECYANOACETAMIDE; 5' PALMITOYLTYROSYLALANYLGLYCYLGLYCYLTYROSYLGLYCYLTYROSYLALANYLALANYLGLYCYLCYSTEINY LALANYLALANINE AMIDE 3'; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRN 163 L; TELOMERASE; TELOMERASE INHIBITOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CELL GROWTH; CONTROLLED STUDY; DRUG CONJUGATION; DRUG POTENTIATION; DRUG SENSITIVITY; GENE AMPLIFICATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TELOMERE;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; GENES, ERBB-2; HUMANS; NEOPLASM PROTEINS; OLIGONUCLEOTIDES; OLIGOPEPTIDES; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-2; RNA; TELOMERASE;

EID: 70349918608     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0201-4     Document Type: Article

References (46)

1. RG Dumitrescu I Cotarla 2005 Understanding breast cancer risk-where do we stand in 2005? J Cell Mol Med 9 208 221 10.1111/j.1582-4934.2005.tb00350.x 10.1111/j.1582-4934.2005.tb00350.x 1:STN:280:DC%2BD2M7lt1Sjtw%3D%3D 15784178
2. A Stevanovic P Lee N Wilcken 2006 Metastatic breast cancer Aust Fam Physician 35 309 312 16680209
3. A Nicolini R Giardino A Carpi, et al. 2006 Metastatic breast cancer: an updating Biomed Pharmacother 60 548 556 10.1016/j.biopha.2006.07.086 10.1016/j.biopha.2006.07.086 1:STN:280:DC%2BD28nptlKrtw%3D%3D 16950593 (Pubitemid 44635086)
4. DJ Slamon B Leyland-Jones S Shak, et al. 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792 10.1056/NEJM200103153441101 10.1056/ NEJM200103153441101 1:CAS:528:DC%2BD3MXisVGktrc%3D 11248153 (Pubitemid 32222155)
5. JS Ross JA Fletcher KJ Bloom, et al. 2004 Targeted therapy in breast cancer Mol Cell Proteomics 3 4 379 398 10.1074/mcp.R400001-MCP200 10.1074/mcp.R400001-MCP200 1:CAS:528:DC%2BD2cXivFCksLs%3D 14762215 (Pubitemid 38702091)
6. CA Hudis 2007 Trastuzumab-mechanism of action and use in clinical practice N Engl J Med 357 39 51 10.1056/NEJMra043186 10.1056/NEJMra043186 1:CAS:528:DC%2BD2sXnsVygu7s%3D 17611206 (Pubitemid 47026733)
7. TM) in breast cancer cells with Her-2/neu oncogene amplification Ann Oncol 16 359 371 10.1093/annonc/mdi090 10.1093/annonc/mdi090 1:STN:280:DC%2BD2M%2FptVGlsg%3D%3D 15642702 (Pubitemid 40458311)
8. G Sledge Jr 2004 HERe-2 stay: the continuing importance of translational research in breast cancer J Natl Cancer Inst 96 725 727 15150294
9. H Burnstein 2005 The distinctive nature of HER-2 positive breast cancers N Engl J Med 353 1652 1654 10.1056/NEJMp058197 10.1056/NEJMp058197 (Pubitemid 41464703)
10. M Tan J Yao D Yu 1997 Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities Cancer Res 57 1199 1205 1:CAS:528: DyaK2sXhvFOitr8%3D 9067293
11. A Choudhury J Charp SK Parapuram, et al. 2004 Small interfering RNA (siRNA) inhibits the expression of the Her2/Neu gene, upregulates HLA class I and induces apoptosis of Her2/Neu positive tumor cell lines Int J Cancer 108 71 77 10.1002/ijc.11497 10.1002/ijc.11497 1:CAS:528:DC%2BD3sXps1entLk%3D 14618618 (Pubitemid 37444446)
12. G Yang KQ Cai JA Thompson-Lanza, et al. 2004 Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression J Biol Chem 279 4339 4345 10.1074/jbc.M311153200 10.1074/jbc.M311153200 1:CAS:528:DC%2BD2cXps12guw%3D%3D 14625284 (Pubitemid 38199022)
13. X Hu F Su L Qin, et al. 2006 Stable RNA interference of ErbB-2 gene synergistic with epirubicin suppresses breast cancer growth in vitro and in vivo Biochem Biophys Res Commun 346 778 785 10.1016/j.bbrc.2006.05.206 10.1016/j.bbrc.2006.05.206 1:CAS:528:DC%2BD28XmtlWrsb4%3D 16781665 (Pubitemid 43913683)
14. JS Ross AJ Fletcher GP Linette, et al. 2003 The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy Oncologist 8 307 325 10.1634/theoncologist.8-4-307 10.1634/theoncologist.8-4-307 1:CAS:528:DC%2BD3sXmvFSqt74%3D 12897328 (Pubitemid 36929717)
15. MD Pegram GE Konecny C O'Callaghan, et al. 2004 Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer J Natl Cancer Inst 96 739 749 1:CAS:528:DC%2BD2cXkt1Sqsbo%3D 15150302
16. R Nahta F Esteva 2007 Trastuzumab: triumphs and tribulations Oncogene 26 3639 3643 10.1038/sj.onc.1210379 10.1038/sj.onc.1210379 (Pubitemid 46842713)
17. BS Goueli R Jankneckt 2004 Upregulation of the catalytic telomerase subunit by the transcription factor ER81 and oncogenic HER2/Neu, Ras, or Raf Mol Cell Biol 24 25 35 10.1128/MCB.24.1.25-35.2004 10.1128/MCB.24.1.25-35.2004 1:CAS:528:DC%2BD2cXhtVWgsQ%3D%3D 14673140 (Pubitemid 38010032)
18. JW Shay S Bacchetti 1997 A survey of telomerase activity in human cancer Eur J Cancer 33 787 791 10.1016/S0959-8049(97)00062-2 10.1016/S0959-8049(97) 00062-2 1:STN:280:DyaK2svis12qug%3D%3D 9282118 (Pubitemid 27239490)
19. NW Kim MA Piatyszek KR Prowse, et al. 1994 Specific association of human telomerase activity with immortal cells and cancer Science 266 2011 2015 10.1126/science.7605428 10.1126/science.7605428 1:CAS:528:DyaK2MXisl2lu7g%3D 7605428
20. B-S Herbert GC Gellert A Hochreiter, et al. 2005 Lipid modification of GRN163, an N3?→P5? thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition Oncogene 24 5262 5268 10.1038/sj.onc.1208760 10.1038/sj.onc.1208760 1:CAS:528:DC%2BD2MXmvFemtr0%3D 15940257 (Pubitemid 41192444)
21. GC Gellert ZG Dikmen WE Wright, et al. 2006 Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer Breast Cancer Res Treat 96 73 81 10.1007/s10549-005-9043-5 10.1007/s10549-005-9043-5 1:CAS:528: DC%2BD28XivVensbY%3D 16319992
22. J Shay 2003 Telomerase therapeutics: telomeres recognized as a DNA damage signal: commentary re: K. Kraemer et al., antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells Clin Cancer Res 9 3521 3525 1:CAS:528:DC%2BD3sXosVOlur4%3D 14506137
23. AE Hochreiter H Xiao EM Goldblatt, et al. 2006 The telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth and metastasis of breast cancer Clin Cancer Res 12 3184 3192 10.1158/1078-0432.CCR-05-2760 10.1158/1078-0432.CCR-05-2760 1:CAS:528:DC%2BD28Xks1Ciu7c%3D 16707619 (Pubitemid 43837368)
24. ZG Dikmen GC Gellert S Jackson, et al. 2005 In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor Cancer Res 65 7866 7873 1:CAS:528:DC%2BD2MXpslaiu7c%3D 16140956
25. MA Cerone JA Londono-Vallejo C Autexier 2006 Mutated telomeres sensitize tumor cells to anticancer drugs independently of telomere shortening and mechanisms of telomere maintenance Oncogene 25 7411 7420 10.1038/sj.onc.1209727 10.1038/sj.onc.1209727 1:CAS:528:DC%2BD28Xht1Kisr7L 16767163 (Pubitemid 44853432)
26. MA Cerone JA Londono-Vallejo C Autexier 2006 Telomerase inhibition enhances the response to anticancer drug treatment in human breast cancer cells Mol Cancer Ther 5 1669 1675 10.1158/1535-7163.MCT-06-0033 10.1158/1535-7163.MCT- 06-0033 1:CAS:528:DC%2BD28XnslWks7c%3D 16891452 (Pubitemid 44323234)
27. MW Djojosubroto AC Chin N Go, et al. 2005 Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma Hepatology 42 1127 1136 10.1002/hep.20822 10.1002/hep.20822 1:CAS:528:DC%2BD2MXht1amtbvI 16114043 (Pubitemid 43112680)
28. kip1 down-regulation is associated with trastuzumab resistance in breast cancer cells Cancer Res 64 3981 3986 10.1158/0008-5472.CAN-03-3900 10.1158/0008-5472.CAN-03- 3900 1:CAS:528:DC%2BD2cXksVKns7k%3D 15173011 (Pubitemid 38697313)
29. CA Ritter M Torres-Perez C Rinehart, et al. 2007 Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network Clin Cancer Res 13 4909 4919 10.1158/1078-0432.CCR-07-0701 10.1158/1078-0432.CCR-07-0701 1:CAS:528:DC%2BD2sXptVGmtLg%3D 17699871 (Pubitemid 47294799)
30. TC Chou P Talalay 1984 Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzym Regul 22 27 55 10.1016/0065-2571(84)90007-4 10.1016/0065-2571(84)90007-4 1:CAS:528:DyaL2cXktlaksLk%3D
31. B-S Herbert AE Hochreiter WE Wright J Shay 2006 Nonradioactive detection of telomerase activity using the telomeric repeat amplification protocol Nat Protoc 1 1583 1590 10.1038/nprot.2006.239 10.1038/nprot.2006.239 1:CAS:528:DC%2BD28Xht1eitLzN 17406450
32. J.S. Bonifacino M. Dasso J.B. Harford J. Lippincott-Schwartz K.M. Yamada (eds). John Wiley and Sons, Inc New York Unit 18.6
33. B-S Herbert JW Shay W Wright 2003 Analysis of telomeres and telomerase JS Bonifacino M Dasso JB Harford J Lippincott-Schwartz KM Yamada (eds) Current protocols in cell biology 3 John Wiley and Sons, Inc New York Unit 18.6 Herbert B-S, Shay JW, Wright W (2003) Analysis of telomeres and telomerase. In: Bonifacino JS, Dasso M, Harford JB, Lippincott-Schwartz J, Yamada KM (eds) Current protocols in cell biology, vol 3. John Wiley and Sons, Inc., New York. Unit 18.6. doi: 10.1002/0471143030.cb1806s20
34. JA Menendez S Ropero R Lupu R Colomer 2004 Dietary fatty acids regulate the activation status of Her-2/neu (c-erb B-2) oncogene in breast cancer cells Ann Oncol 15 1719 1721 10.1093/annonc/mdh442 10.1093/annonc/mdh442 1:STN:280:DC%2BD2crkslSrsA%3D%3D 15520077 (Pubitemid 39567289)
35. TM) in HER2-overexpressing breast cancer cells BMC Cancer 7 80 10.1186/1471-2407-7-80 10.1186/1471-2407-7-80 17490486 (Pubitemid 46864916)
36. J Gomez-Millan EM Goldblatt SM Gryaznov, et al. 2007 Specific telomere dysfunction induced by GRN163L increases radiation sensitivity in breast cancer cells Int J Radiat Oncol Biol Phys 67 897 905 10.1016/j.ijrobp.2006.09.038 1:CAS:528:DC%2BD2sXhsFKmtLk%3D 17175117 (Pubitemid 46215875)
37. K Liang Y Lu W Jin, et al. 2003 Sensitization of breast cancer cells to radiation by trastuzumab Mol Cancer Ther 2 1113 1120 1:CAS:528: DC%2BD3sXovFCqtLo%3D 14617784
38. RJ Ward C Autexier 2005 Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment Mol Pharm 68 779 786 1:CAS:528:DC%2BD2MXpvFWktro%3D
39. C Ip 1997 Review of the effects of trans fatty acids, oleic acid, n-3 polyunsaturated fatty acids, and conjugated linoleic acid on mammary carcinogenesis in animals Am J Clin Nutr 66 1523S 1529S 1:CAS:528: DyaK2sXnslSku78%3D 9394710
40. W Hardman 2004 (n-3) Fatty acids and cancer therapy J Nutr 134 3427S 3430S 1:CAS:528:DC%2BD2cXhtVOmtLvJ 15570049
41. D Hwang S Rhee 1999 Receptor-mediated signaling pathways: potential targets of modulation by dietary fatty acids J Clin Nutr 70 545 556 1:CAS:528:DyaK1MXmsFCgur8%3D
42. Y Maida S Kyo T Kanaya, et al. 2002 Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway Oncogene 21 4071 4079 10.1038/sj.onc.1205509 10.1038/sj.onc.1205509 1:CAS:528:DC%2BD38XltVymtLY%3D 12037663 (Pubitemid 34712874)
43. Z Ge C Liu M Björkholm, et al. 2006 Mitogen-activated protein kinase cascade-mediated histone H3 phosphorylation is critical for telomerase reverse transcriptase expression/telomerase activation induced by proliferation Mol Cell Biol 26 230 237 10.1128/MCB.26.1.230-237.2006 10.1128/MCB.26.1.230-237.2006 1:CAS:528:DC%2BD28Xjslaqtrw%3D 16354694
44. R Nahta LXH Yuan Y Du, et al. 2007 Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling Mol Cancer Ther 6 667 674 10.1158/1535-7163.MCT-06-0423 10.1158/1535-7163.MCT-06-0423 1:CAS:528:DC%2BD2sXhvVWrsbc%3D 17308062 (Pubitemid 46332467)
45. LL Smith HA Coller JM Roberts 2003 Telomerase modulates expression of growth-controlling genes and enhances cell proliferation Nat Cell Biol 5 474 479 10.1038/ncb985 10.1038/ncb985 1:CAS:528:DC%2BD3sXjtlalsrs%3D 12717449 (Pubitemid 36592272)
46. K Kraemer U Schmidt S Fuessel, et al. 2006 Microarray analyses in bladder cancer cells: inhibition of hTERT expression down-regulates EGFR Int J Cancer 119 1276 1284 10.1002/ijc.21975 10.1002/ijc.21975 1:CAS:528:DC%2BD28XovVOru7s%3D 16615118 (Pubitemid 44258800)